Market News
Biogen Advances Alzheimer’s Drug to Phase 3 Despite Mixed Trial Data
Biogen just decided to move forward with a promising but puzzling Alzheimer's drug candidate into late-stage testing despite some disappointing...
14/05/2026
3 views